Research Article

Urinary Excretion of Neutrophil Gelatinase-Associated Lipocalin in Diabetic Rats

Abraham Said Arellano-Buendía, 1 Fernando Enrique García-Arroyo, 1 Magdalena Cristóbal-García, 1 María Lilia Loredo-Mendoza, 2 Edilia Tapia-Rodríguez, 1 Laura Gabriela Sánchez-Lozada, 1 and Horacio Osorio-Alonso 1

1 Renal Pathophysiology Laboratory, Department of Nephrology, Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano 1, Sección XVI, Tlatlpan, 14080 México City, DF, Mexico
2 Histopathology Laboratory, Research Subdivision, School of Medicine, Universidad Panamericana, Donatello 43, 03910 México City, DF, Mexico

Correspondence should be addressed to Horacio Osorio-Alonso; horace.33@yahoo.com.mx

Received 23 May 2014; Revised 14 July 2014; Accepted 16 July 2014; Published 27 August 2014

Academic Editor: Ryuichi Morishita

Copyright © 2014 Abraham Said Arellano-Buendía et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recent studies suggest that tubular damage precedes glomerular damage in the progression of diabetic nephropathy. Therefore, we evaluated oxidative stress and urinary excretion of tubular proteins as markers of tubular dysfunction. Methods. Diabetes was induced in rats by streptozotocin administration (50 mg/kg). Oxidative stress was assessed by measuring the activity of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD); additionally, expression levels of 3-nitrotyrosine (3-NT), 4-hydroxynonenal (4-HNE), and oxidized protein (OP) were quantified. Whole glomerular filtration rate (GFR) was measured. Urinary excretion of neutrophil gelatinase-associated lipocalin (uNGAL), osteopontin (uOPN), and N-acetyl-β-D-glucosaminidase (uNAG) was also determined. Results. Diabetic rats showed an increase in uNGAL excretion 7 days following induction of diabetes. Diuresis, proteinuria, albuminuria, creatinine clearance, and GFR were significantly increased by 30 days after induction. Furthermore, there was an increase in both CAT and SOD activity, in addition to 3-NT, 4-HNE, and OP expression levels. However, GPx activity was lower. Serum levels of NGAL and OPN, as well as excretion levels of uNGAL, uOPN, and uNAG, were increased in diabetics. Tubular damage was observed by 7 days after diabetes induction and was further aggravated by 30 days after induction. Conclusion. The tubular dysfunction evidenced by urinary excretion of NGAL precedes oxidative stress during diabetes.

1. Introduction

Diabetic nephropathy (DN) is now the primary cause of end stage renal disease (ESRD), described as a worldwide medical catastrophe. Although several lines of evidence have suggested that poor glycemic control undoubtedly plays a significant role [1, 2], the metabolic events responsible for triggering DN are not well understood.

During diabetes, persistent hyperglycemia through glucose autoxidation and defective antioxidant defenses causes increased production of reactive oxygen species (ROS) [3, 4]. This excessive ROS production and subsequent oxidative damage have been suggested as common outcomes of diabetes, which finally culminates in DN [4].

The impairment of renal function in DN patients has long been diagnosed using biochemistry tools, including measurement of serum creatinine (Scr) and blood urea nitrogen (BUN). However, these are not reliable markers of early loss of renal function, thus delaying therapeutic interventions in order to stop or slow progression of renal damage. Microalbuminuria has recently emerged as a sensitive marker of early renal damage; however, this measurement also lacks the sensitivity to detect the earliest changes in renal function.
Renal damage markers, particularly those associated with tubular dysfunction such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and kidney injury molecule (KIM-1), have recently attracted attention as sensitive and specific biomarkers to detect early kidney damage [5, 6]. Extensive reports have verified the prognostic and diagnostic value of these markers in various renal disorders, including DN [5–7].

NGAL is a member of the lipocalin family originally identified as a 25-kDa protein covalently associated with human matrix metalloproteinase 9 (MMP-9) in human neutrophils [8]. It is primarily stored in specific granules of neutrophils but also expressed at very low levels in the kidney, trachea, lungs, stomach, and colon [9]. NGAL has diverse functions, including transporting and activating MMP-9, inducing apoptosis, and regulating the immune response. In pathological processes, evidence suggests that NGAL is tightly associated with a series of renal dysfunctions. NGAL is one of the most robustly expressed proteins in ischemic or nephrotic kidney injury in experimental models [10] and in humans [11]. Serum NGAL has been described as a sensitive and specific biomarker for early identification
of acute kidney injury following cardiac surgery [11] and a novel biomarker in children with chronic kidney diseases [12].

Because diabetic nephropathy represents one of the most devastating outcomes during the progression of diabetes mellitus, early detection strategies to diagnose loss of renal function would be of utmost value to improve quality of life. Therefore, we investigated the activity of endogenous antioxidant enzymes, oxidative stress in plasma and renal tissue, and urinary excretion of tubular proteins as candidate of early biomarkers of tubular injury during diabetes.

2. Methods

2.1. Reagents. Streptozotocin (STZ), 4-nitrophenyl-N-acetyl-β-D-glucosaminide, 2,4-dinitrophenylhydrazine, xanthine, nitroblue tetrazolium (NBT), xanthine oxidase, glutathione reductase (GR), and reduced glutathione (GSH) were purchased from Sigma (St. Louis, MO, USA). All other chemicals used were of the highest analytical grade available.

2.2. Experimental Design. All animal procedures were performed in accordance with the Mexican Federal Regulation for Animal Experimentation and Care (NOM-062-ZOO-2001) and were approved by the Bioethics and Investigation Committees of the Instituto Nacional de Cardiología "Ignacio Chávez."

Adult male Wistar rats were used at 10–14 weeks of age (250–300 g). Animals were randomly divided into three groups (n = 16 each group): control (C), diabetic (D), and diabetic treated with insulin (DI). Diabetes was induced by a single administration of streptozotocin (STZ) (50 mg/kg i.p.) dissolved in citrate buffer (0.1 M, pH 4.5). The control group received the same volume of citrate buffer. Blood glucose concentration was determined (Accu-Chek sensor comfort, Roche Diagnostics) 72 h after STZ administration, and only rats with glucose measurements over 20.0 mmol/L were considered diabetic for further studies.

Treatment was initiated after confirmation of diabetes. To analyze early renal changes induced by diabetes, a set of animals was sacrificed after 7 days of followup, after confirmation of diabetes (8 rats/group). The remaining rats were studied after 30 days of followup (8 rats/group). All experimental groups were maintained on laboratory diet and water ad libitum.

Insulin was administered i.p. (Humulin; Eli Lilly and Company, Indianapolis, IN) in an initial dose of 6 IU followed by 2 to 4 IU daily, depending on morning blood glucose values.

Rats were placed in metabolic cages (Nalgene, Rochester, NY) and urine (24 h) was collected at 7 and 30 days after diabetes induction. Urine samples were centrifuged at 5000 g for 15 minutes to remove debris, and the supernatant was vortexed and analyzed. The urinary variables measured were diuresis, glucose, creatinine clearance (IL 300 plus, clinical chemistry analyzer), proteinuria, and microalbuminuria (Albumin Rat ELISA Kit, Abcam). We evaluated the urinary excretion of NGAL, osteopontin (OPN), and NAG as biomarkers of tubular injury.

2.3. Evaluation of Systemic Markers of Oxidative Stress

2.3.1. Preparation of the Erythrocyte Samples. At each time point (7 and 30 days), 0.5 milliliters of blood was taken from
2.3.2. Catalase Assay. CAT activity was measured in hemolysates by a method based on the disappearance of H$_2$O$_2$ from a solution containing 30 mmol/L H$_2$O$_2$ in 10 mmol/L potassium phosphate buffer (pH 7) at 240 nm [3]. The results were expressed as U/mL.

2.3.3. Glutathione Peroxidase Assay. The glutathione peroxidase (GPx) activity in erythrocyte lysates was assessed as previously described [3]. The results were expressed as U/mL.

2.3.4. Superoxide Dismutase Assay. Superoxide dismutase (SOD) activity in erythrocyte lysates was measured by a
Figure 4: Immunoblot and semiquantitative analysis of NGAL levels. 7 days (a) and (b); 30 days (c) and (d). Plasma (a) and (c) and urine (b) and (d). C: control, D: diabetic, and DI: diabetic insulin treated. Data are mean ± SEM of eight animals in each group. *P < 0.05 versus C; **P < 0.05 versus D.

competitive inhibition assay using xanthine-xanthine oxidase system to reduce NBT as previously reported [3]. Results were expressed as U/mL.

2.3.5. Nitrotyrosine Measurement. Plasma protein concentrations were determined using the Bradford method [4]. Equal amounts of protein (15 μg) were denatured in gel loading buffer by heating at 85°C for 5 minutes before loading onto 10% SDS-polyacrylamide gels. After electrophoretic separation, samples were transferred to polyvinylidene difluoride (PVDF) membranes and incubated at 4°C overnight with primary antibody (1:1000) diluted in PBST. The protein bands were visualized with enhanced chemiluminescence reagents (ECL Plus Western Blotting Detection System, Amersham Pharmacia Biotech), and analysis and intensity quantification were conducted using Kodak Electrophoresis Documentation and Analysis System 290 (EDAS 290).

2.4. Evaluation of Renal Markers of Oxidative Stress

2.4.1. Determination of Lipid Peroxidation [4-hydroxynonenal (4-HNE)]. For the 4-HNE assay, 50 mg of kidney cortex or medulla was homogenized in ice-cold PBS; the colorimetric assay was performed in accordance to Gérard-Monnier et al.
Figure 5: Immunoblot and semiquantitative analysis of OPN levels. 7 days after diabetes induction (a) and (b); 30 days after diabetes induction (c) and (d). Plasma (a) and (c) and urine (b) and (d). C: control, D: diabetic, and DI: diabetic insulin treated. Data are mean ± SEM of eight animals in each group. *P < 0.05 versus C; †P < 0.05 versus D.

[13] and Erdelmeier et al. [14]. The results were expressed as nmol of 4-HNE/mg protein.

2.4.2. Measurement of Oxidized Protein (Carbonyls Protein). The determination of carbonyl groups in the proteins was measured using the reaction with 2,4-dinitrophenylhydrazine (DNPH) described by Levine et al. [15] with slight modifications. Protein carbonyl groups were estimated by using the molar absorption coefficient of 22,000 M⁻¹·cm⁻¹ for DNPH derivatives, and its concentration was expressed as nmol carbonyl groups/mg protein. Guanidine solution was used as a blank.

2.5. Glomerular Filtration Rate. The glomerular filtration rate (GFR) was estimated by polyfructosan clearance method as previously described [16].

2.6. Urinary Excretion of Renal Tubule Damage Biomarkers

2.6.1. Urinary Excretion of NGAL and OPN. Urinary excretion of NGAL and osteopontin (OPN) was assayed by immunoblotting. Sample volumes corresponding to 15 μg of total protein were precipitated on ice for 30 min with 10% (w/v) trichloroacetic acid in PBS. Samples were then centrifuged at 13,100 g for 10 min at 4°C before washing
pellets twice with ice-cold acetone. The samples were air-
dried and dissolved in Laemmli buffer (62.5 mmol/L Tris-
HCl (pH 6.8), 10% (w/v) glycerol, 2% (w/v) SDS, 5% (w/v)
2-mercaptoethanol, and 0.05% (w/v) bromophenol blue)
followed by heating at 95°C for 5 min. Samples were loaded
in SDS-PAGE gels as previously described [16]. Protein
bands were visualized and intensity quantified as previously
described [16]. To account for differences in hydration and
urine concentration, the results were normalized to urine
creatinine.

2.6.2. Measurement of N-acetyl β-D-glucosaminidase (NAG) Activity. For the determination of NAG activity in urine samples, 4-nitrophenyl-N-acetyl-β-D-glucosaminide was used as substrate. One unit of enzymatic activity (U) represents the amount of enzyme, which hydrolyses one μmol of substrate per min at 37°C [17,18]. The results were expressed as U/24 h.

2.7. Histopathological Evaluation. To evaluate the tubular injury, the kidneys were fixed in 10% formalin in PBS and embedded in paraffin. Kidney sections (3 μm) were obtained and stained with hematoxylin and eosin and later on analyzed under light microscopy (AxioPhot2 Zeiss, Germany). All slides were analyzed in a blinded fashion.

2.8. Statistical Analysis. Data are expressed as the mean ± SEM. Statistical differences among groups were calculated using ANOVA with Bonferroni correction (Prism 4.0; GraphPad Software, San Diego, CA, USA). Significance for all statistical comparisons was set at P < 0.05.

3. Results

3.1. Physiologic Characteristics. After 7 days of followup, diabetic rats were hyperglycemic and glycosuric compared to control. Insulin treatment prevented these changes (Table 1). There were no significant differences between experimental groups in proteinuria, albuminuria, serum creatinine, urinary creatinine, or creatinine clearance. Because renal functional changes were imperceptible at this early time point, we did not measure GFR.

After 30 days, diabetic rats were hyperglycemic and glycosuric, with high diuresis, proteinuria, albuminuria, and low body weight compared to the control group and diabetic rats treated with insulin (Table 1). Furthermore, creatinine clearance was increased in the diabetic rats compared to the control group, suggesting glomerular hyperfiltration. This well-known effect induced by diabetes was demonstrated by a significant increase in polyfructosan clearance. Insulin treatment effectively prevented glomerular hyperfiltration in diabetic rats. Additionally, body weight, serum creatinine, diuresis, urinary creatinine, proteinuria, albuminuria, and blood glucose levels were not statistically different between diabetic insulin-treated and control group (Table 1).

3.2. Evaluation of Markers of Systemic Oxidative Stress. Hyperglycemia-induced oxidative stress was assessed by measuring the activity of antioxidant enzymes CAT, GPx, and SOD in erythrocyte lysates and by determination of serum nitrotyrosine levels using western blot analysis. At 7 days, there were no statistical differences in the activities of CAT, GPX, and SOD (Table 2) between diabetic and control rats. However, after 30 days, CAT and SOD activity was significantly increased in diabetic rats (Figures 1(a) and 1(c) resp.), while GPx activity was decreased (Figure 1(b)). These alterations in antioxidant enzyme activity were associated with a significant increase in nitrotyrosine levels in diabetic rats (Figures 2(a) and 2(b)). However, insulin treatment preserved normal enzymatic activity and nitrotyrosine levels.

3.3. Evaluation of Renal Markers of Oxidative Stress. To assess local oxidative stress, we evaluated lipid and protein oxidation by measuring tissue content of 4-hydroxynonenal (4-HNE) and carbonyl proteins. Lipid and protein oxidation were similar among all experimental groups in the renal cortex and medulla after 7 days of the diabetes induction (Table 2). However, 4-HNE and carbonyl protein content in renal cortex and medulla were significantly increased in diabetic rats compared to the control group after 30 days (Figure 3). This diabetes-induced renal oxidative stress was prevented by insulin treatment (Figure 3).

Together, these findings suggest that during diabetes systemic and renal oxidative stress are a secondary effect of hyperglycemia.

3.4. Urinary Excretion of Tubular Damage Biomarkers. Seven days after induction of diabetes, there were no changes in serum expression of NGAL and OPN (Figures 4(a) and 5(a)). In contrast, urinary excretion of uNGAL was significantly higher in diabetic rats compared to healthy controls and diabetic insulin-treated animals (Figure 5(b)). The other
evaluated biomarkers (OPN and NAG) did not differ among the studied groups.

Thirty days after diabetes induction, NGAL and OPN serum levels were higher in serum from the diabetic group compared to the control group (Figures 4(c) and 5(c)). These results were associated with increased urinary excretion of NGAL and OPN in diabetic rats (Figures 4(d) and 5(d)). Moreover, NAG urinary excretion was increased in diabetic rats compared to control rats (Figure 6). This increase in urinary excretion of tubular proteins was prevented by insulin treatment.

### Table 1: Biochemical and physical characteristics of experimental groups.

|                      | Control 7 days | Diabetic 7 days | Diabetic insulin treated 7 days |
|----------------------|---------------|-----------------|-------------------------------|
| Body weight (g)      | 259 ± 3.34    | 410.6 ± 8.13    | 263.5 ± 7.28*                 |
| Blood glucose (mg/dL)| 91.16 ± 5.04  | 91.75 ± 4.27    | 402.12 ± 21.47*              |
| Serum creatinine (mg/dL) | 0.45 ± 0.03 | 0.47 ± 0.08    | 0.48 ± 0.05                   |
| Diuresis (mL/24hrs)  | 14.45 ± 1.47  | 16.3 ± 4.3      | 22.82 ± 3.72*                |
| Glycosuria (mg/dL)   | 1.06 ± 0.06   | 0 ± 0           | 4797.1 ± 148.4*              |
| Urine creatinine (mg/mL/24 hrs) | 6.26 ± 0.33 | 6.52 ± 1.56     | 8.21 ± 0.61                   |
| Proteinuria (mg/24 hrs) | 19.36 ± 1.79  | 14.43 ± 1.51    | 25.87 ± 2.51                 |
| Glomerular filtration rate (mL/min) | ND | 1.39 ± 0.10          | 3.59 ± 0.46*                |
| Albuminuria (µg/24 hrs) | 206 ± 23.42  | 189.4 ± 26.61   | 252 ± 40.19                  |
| Creatinine clearance (mL/min) | 0.99 ± 0.09  | 1.02 ± 0.18     | 0.99 ± 0.08                  |

|                      | Control 30 days | Diabetic 30 days | Diabetic insulin treated 30 days |
|----------------------|---------------|-----------------|-------------------------------|
| Body weight (g)      | 259 ± 3.34    | 410.6 ± 8.13    | 263.5 ± 7.28*                 |
| Blood glucose (mg/dL)| 91.16 ± 5.04  | 91.75 ± 4.27    | 402.12 ± 21.47*              |
| Serum creatinine (mg/dL) | 0.45 ± 0.03 | 0.47 ± 0.08    | 0.48 ± 0.05                   |
| Diuresis (mL/24hrs)  | 14.45 ± 1.47  | 16.3 ± 4.3      | 22.82 ± 3.72*                |
| Glycosuria (mg/dL)   | 1.06 ± 0.06   | 0 ± 0           | 4797.1 ± 148.4*              |
| Urine creatinine (mg/mL/24 hrs) | 6.26 ± 0.33 | 6.52 ± 1.56     | 8.21 ± 0.61                   |
| Proteinuria (mg/24 hrs) | 19.36 ± 1.79  | 14.43 ± 1.51    | 25.87 ± 2.51                 |
| Glomerular filtration rate (mL/min) | ND | 1.39 ± 0.10          | 3.59 ± 0.46*                |
| Albuminuria (µg/24 hrs) | 206 ± 23.42  | 189.4 ± 26.61   | 252 ± 40.19                  |
| Creatinine clearance (mL/min) | 0.99 ± 0.09  | 1.02 ± 0.18     | 0.99 ± 0.08                  |

### Table 2: Evaluation of oxidative stress at 7 days.

|                      | Control | Diabetic | Diabetic-insulin treated |
|----------------------|---------|----------|-------------------------|
| CAT (U/mL)           | 1780 ± 294.7 | 1459 ± 109.6 | 1791 ± 205.3 |
| GPx (U/mL)           | 106.2 ± 1.19 | 116.1 ± 2.46 | 109.1 ± 3.17 |
| SOD (U/mL)           | 651.8 ± 9.52 | 662.0 ± 10.96 | 683.6 ± 6.79 |
| Carbonyl content in Ctx (nmol/mg protein) | 1.75 ± 0.90 | 4.36 ± 1.67 | 2.72 ± 0.25 |
| Carbonyl content in Med (nmol/mg protein) | 13.73 ± 3.01 | 791 ± 2.28 | 7.26 ± 2.89 |
| 4-HNE content in Ctx (nmol/mg protein) | 0.22 ± 0.19 | 0.89 ± 0.22 | 0.83 ± 0.27 |
| 4-HNE content in Med (nmol/mg protein) | 0.41 ± 0.25 | 1.09 ± 0.28 | 1.04 ± 0.30 |

CAT: catalase, GPx: glutathione peroxidase, SOD: superoxide dismutase, Ctx: renal cortex, Med: renal medulla, and 4-HNE: 4-hydroxynonenal. Data are mean SEM of 8 animals in each group. * P < 0.05 versus control; † P < 0.05 versus diabetic.

### 3.5. Histological Analysis.

Histological analysis of the kidney from control rats revealed normal glomeruli and proximal and distal convoluted tubules 7 days after diabetes induction (Figure 7(a)). The kidney of diabetic rats showed vacuolar degeneration of the tubular epithelium (Figure 7(b)); these changes were absent in diabetic insulin-treated rats (Figure 7(c)). Thirty days after diabetes induction, epithelial tubular cells showed vacuolization and cell detachment, with cellular debris detected in the tubular lumen (Figure 7(e)). Insulin treatment in diabetic rats greatly attenuated these lesions (Figure 7(f)).

In summary, insulin treatment in diabetic rats significantly blocked the increase in oxidative stress and urinary excretion of tubular injury markers.

### 4. Discussion

Diabetic nephropathy is one of the leading causes of chronic kidney diseases worldwide. It is therefore of utmost importance to find early markers for diabetes-associated renal disease in order to provide prompt therapeutic interventions that retard progression in patients at risk for developing chronic disease. Therefore, the aim of this study was to evaluate if markers of oxidative stress or urinary biomarkers of renal damage might be useful tools to detect early signs of renal diabetic damage.

Diabetic nephropathy has traditionally been considered as a glomerular disease; however, it is now widely accepted that the rate of deterioration in renal function correlates best with the degree of tubulointerstitial damage [19]. In fact, tubular involvement may occur before glomerular damage develops; several tubular proteins and low molecular weight enzymes are detectable in urine before the appearance of microalbuminuria and the rise in SrC [5–7, 20]. Currently, the most frequently evaluated urinary enzymes include NAG, NGAL, and KIM-1 [6, 7, 17, 20].

To investigate oxidative stress and urinary excretion of tubular markers, we used diabetic rats at 7 and 30 days after diabetes induction. At 7 days after induction, the diabetic rats were hyperglycemic but did not show any alternations in oxidative stress markers. However, at 30 days after induction the diabetic rats presented with diuresis, glycosuria, proteinuria, albuminuria, and glomerular hyperfiltration.
Glomerular hyperfiltration and proximal tubular hyperreabsorption are among the distinctive features of early diabetic nephropathy [21]. Additionally, systemic oxidative stress data was characterized by a significant increase in CAT and SOD activity and 3-NT levels; in contrast, GPx activity was decreased. Tissue oxidative stress was demonstrated by a high renal content of 4-HNE and carbonyl proteins in diabetic rats. These data are consistent with other studies that report oxidative stress in rats and patients with hyperglycemia, supporting the hypothesis that oxidative stress is a general pathophysiological pathway in the development of diabetic nephropathy [3, 22–25].

In the present study, glomerular hyperfiltration was associated with renal oxidative stress. There is no definitive mechanism for the role of oxidative stress in the induction of hyperfiltration; however, some hypotheses imply that increased mitochondrial superoxide production is a major mechanism of microvascular damage in diabetes [26]. Structural alterations in afferent and efferent arterioles may partially explain the functional changes that lead to glomerular hyperfiltration, as has been observed in other models [27].

Diabetes-stimulated renal damage was detectable in urinary excretion of biomarkers. A significant increase in NGAL excretion was apparent by 7 and 30 days after diabetes induction and (d)–(f) from animals euthanized 30 days after induction. (a) and (d) Kidneys from control rats show no lesions. (b) Diabetic animal (7 days) exhibits tubular epithelium vacuolar degeneration (arrows). (e) Diabetic rat (30 days) shows vacuolization (arrows), detachment, and debris of the tubular epithelial cells in the tubular lumen (arrowheads). (c) and (f) Diabetic insulin treated rats, with no abnormalities and considerable attenuation of these changes, respectively. (200x original magnification).
induction. Upregulation of NGAL, which was detected in urine but not in plasma, suggests that NGAL is produced primarily in renal tissue, specifically in the tubule [22]. Our data suggest that the early increase in urinary excretion of NGAL is likely dependent on hyperglycemia rather than oxidative stress. In order to confirm these results, we administered the antioxidant Tempol (15 mg/kg/day) to diabetic rats during 7 days. Treatment with Tempol did not modify urinary excretion of NGAL in diabetic animals (data not shown). Therefore, these results support the notion that the early increase in urine NGAL is not dependent on increased oxidative stress. Thirty days after diabetes induction, NGAL and OPN levels were increased in both the serum and urine of diabetic rats. These data suggested that tubular injury had occurred. This was supported by the epithelial tubular damage observed histologically and characterized by vacuolar degeneration and the presence of detached cells and debris in the tubule lumen. These results suggested that tubular injury was mediated by the diabetic environment and, importantly, that urinary excretion of OPN, NAG, and in particular NGAL may be early detected markers for renal damage during diabetes.

Other studies have reported increases in urinary excretion of kidney injury markers, including lipocalin 2 (Lcn-2), OPN, α-glutathione S-transferase (α-Gst), μ-glutathione S-transferase (μ-Gst), and beta-2 microglobulin (β2m) in diabetes [22, 28] and ischemic or nephrotic injury in both animals and humans [11, 12, 28]. However, to our knowledge this is the first study evaluating the temporal expression pattern of urinary biomarkers NGAL, OPN, and NAG in early experimental diabetes. Serum NGAL has been described as a sensitive and specific biomarker for early identification of kidney injury following cardiac surgery [11], for CKD in children [12] and for diabetic patients with and without microalbuminuria [7, 29–31].

It has also been reported that OPN levels inversely correlate with decreased glomerular filtration rate, severity of nephropathy, and coronary artery disease during the progression of human and experimental diabetes [32–34]. Urinary NAG is known to be distributed more widely in the nephron and released as a result of tubular damage [35]. Our study showed that the uNAG was significantly higher in diabetic groups and was associated with duration of diabetes. These data are consistent with other reports, which state that excretion of NAG indicates proximal tubular dysfunction [7, 22, 36, 37].

Tubular cell injury impairs reabsorption, which in turn leads to increased excretion of these nonreabsorbed proteins. Thus, the increased excretion rates observed in our study reflect tubular cell damage.

5. Conclusions

The appearance of NGAL in urine is associated with hyperglycemia and precedes the development of oxidative stress and the appearance of other urinary markers or elevations in serum creatinine, albuminuria, OPN, and NAG. This suggests that tubular damage may precede glomerular injury. Our results suggest that NGAL, OPN, and NAG might be used as early, sensitive, and noninvasive urinary biomarkers of renal injury. More studies are needed to confirm our results and to detect the underlying mechanisms of tubular injury in diabetic nephropathy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by the National Council of Science and Technology (CONACYT) Mexico: Research Grants were given to Sánchez-Lozada Laura G. (no. 133232), to Tapia-Rodríguez Edilia (no. 167949), and to Osorio-Alonso Horacio (no. 155604). The study was also partially funded by INC “Ignacio Chávez” Basic Research Sub Direction funds. Claudia Rangel-Barajas and Israel Coronel-Morales critically revised the paper.

References

[1] “Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group,” Kidney International, vol. 47, no. 6, pp. 1703–1720, 1995.
[2] H. J. Bangstad, R. Østerby, K. Dahl-Jørgensen, K. J. Berg, A. Hartmann, and K. F. Hanssen, “Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy,” Diabetologia, vol. 37, no. 5, pp. 483–490, 1994.
[3] H. Osorio, I. Coronel, A. Arellano et al., “Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 542042, 7 pages, 2012.
[4] H. Ha and H. B. Lee, “Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney,” Nephrology, vol. 10, supplement 2, pp. S7–S10, 2005.
[5] M. Von Eynatten, M. Baumann, U. Heemann et al., “Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes,” European Journal of Clinical Investigation, vol. 40, no. 2, pp. 95–102, 2010.
[6] K. Damman, D. J. van Veldhuisen, G. Navis et al., “Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate,” Heart, vol. 96, no. 16, pp. 1297–1302, 2010.
[7] W. Fu, S. Xiong, Y. Fang et al., “Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study,” Endocrine, vol. 41, no. 1, pp. 82–88, 2012.
[8] L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,” Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425–10432, 1993.
[9] J. B. Cowland and N. Borregaard, “Molecular characterization and pattern of tissue expression of the gene for neutrophil...
gelatinase-associated lipocalin from humans," Genomics, vol. 45, no. 1, pp. 17–23, 1997.

[10] J. Mishra, K. Mori, Q. Ma, C. Kelly, J. Barasch, and P. Devarajan, "Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity," The American Journal of Nephrology, vol. 24, no. 3, pp. 307–315, 2004.

[11] J. Mishra, C. Dent, R. Tarabishi et al., "Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery," The Lancet, vol. 365, no. 9466, pp. 1231–1238, 2005.

[12] M. M. Mitsnefes, T. S. Kathman, J. Mishra et al., "Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease," Pediatric Nephrology, vol. 22, no. 1, pp. 101–108, 2007.

[13] D. Gérard-Monnier, I. Erdelmeier, K. Régnard, N. Moze-Henry, J. Yadan, and J. Chaudière, "Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4- hydroxyalkenals: analytical applications to a colorimetric assay of lipid peroxidation," Chemical Research in Toxicology, vol. 11, no. 10, pp. 1176–1183, 1998.

[14] I. Erdelmeier, D. Gérard-Monnier, J. C. Yadan, and J. Chaudière, "Reactions of N-methyl-2-phenylindole with malondialdehyde and 4- hydroxyalkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation," Chemical Research in Toxicology, vol. 11, no. 10, pp. 1184–1194, 1998.

[15] R. L. Levine, D. Garland, C. N. Oliver et al., "Determination of carbonyl content in oxidatively modified proteins," Methods in Enzymology, vol. 186, pp. 464–478, 1990.

[16] H. Osorio, R. Bautista, A. Rios, M. Franco, J. Santamaria, and B. Escalante, "Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats," Diabetes Research and Clinical Practice, vol. 86, no. 3, pp. e46–e49, 2009.

[17] J. Škrha, J. Perušičová, P. Štolba, V. Stibor, and J. Páv, "Comparison of N-acetyl-β-glucosaminidase and albuminuria with clinical finding of microangiopathy in type I diabetes mellitus," Clinica Chimica Acta, vol. 166, no. 2-3, pp. 135–141, 1987.

[18] J. M. Wellwood, R. G. Price, B. G. Ellis, and A. E. Thompson, "A note on the practical aspects of the assay of N-acetyl-β-glucosaminidase in human urine," Clinica Chimica Acta, vol. 69, no. 1, pp. 83–91, 1976.

[19] A. Bohle, M. Wehrmann, O. Bogenschutz, C. Batz, C. A. Muller, and G. A. Muller, "The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis," Pathology Research and Practice, vol. 187, no. 2-3, pp. 251–259, 1991.

[20] K. Jung, M. Pergande, E. Schinke, K. P. Ratzmann, and A. Illiu, "Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy," Clinical Chemistry, vol. 34, no. 3, pp. 544–547, 1988.

[21] R. C. Blantz and P. Singh, "Glomerular and tubular function in the diabetic kidney," Advances in Chronic Kidney Disease, vol. 21, no. 3, pp. 297–303, 2014.

[22] T. Kuwabara, K. Mori, M. Mukoyama et al., "Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons," Kidney International, vol. 75, no. 3, pp. 285–294, 2009.

[23] K. Horie, T. Miyata, K. Maeda et al., "Immunohistochemical colocalization of glyoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy," Journal of Clinical Investigation, vol. 100, no. 12, pp. 2995–3004, 1997.

[24] H. Ha, C. Kim, Y. Son, M. H. Chung, and K. H. Kim, "DNA damage in the kidneys of diabetic rats exhibiting microalbuminuria," Free Radical Biology and Medicine, vol. 16, no. 2, pp. 271–274, 1994.

[25] C. Sato-Horiguchi, D. Ogawa, J. Wada et al., "Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice," Nephron: Experimental Nephrology, vol. 121, no. 3-4, pp. e97–e108, 2013.

[26] M. Brownlee, "The pathobiology of diabetic complications: a unifying mechanism," Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005.

[27] E. Tapia, M. Franco, L. G. Sánchez-Lozada et al., "Mycohenolate mofetil prevents arteriopathy and renal injury in subtotal ablation despite persistent hypertension," Kidney International, vol. 63, no. 3, pp. 994–1002, 2003.

[28] R. L. Rouse, S. R. Stewart, K. L. Thompson, and J. Zhang, "Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media," Toxicologic Pathology, vol. 41, no. 4, pp. 662–680, 2013.

[29] A. A. Al-Refai, S. I. Tayel, A. Ragheb, A. G. Dala, and A. Zahran, "Urinary neutrophil Gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria," Open Journal of Nephrology, vol. 4, pp. 37–46, 2014.

[30] H. S. Assal, S. Tawfeek, D. El-Lebedy, and E. H. Thabet, "Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus," Clinical Medicine Insights: Endocrinology and Diabetes, vol. 6, pp. 7–13, 2013.

[31] S. Uslu, B. Efe, Ö. Alataş et al., "Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients," Journal of Nephrology, vol. 18, no. 5, pp. 559–567, 2005.

[32] X. Yan, M. Sano, L. Lu et al., "Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus," Cardiovascular Diabetology, vol. 9, article 70, p. 8, 2010.

[33] J. Lorenzen, R. Shah, A. Biser et al., "The role of osteopontin in the development of albuminuria," Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 884–890, 2008.

[34] H. Yamaguchi, M. Igarashi, A. Hirata et al., "Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients," Endocrine Journal, vol. 51, no. 5, pp. 499–504, 2004.

[35] J. W. Fischer, C. Tschöpe, A. Reinecke, C. M. Giachelli, and T. Unger, "Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin," Diabetes, vol. 47, no. 9, pp. 1512–1518, 1998.

[36] M. A. Fathy, M. M. Elkady, H. A. Fathy, S. A. Awad, and A. A. Elmenshawy, "Estimation of renal tubal markers for predicting early stage diabetic nephropathy in Egyptian children with type I diabetes mellitus," Research Journal of Medicine & Medical Sciences, vol. 4, no. 2, p. 209, 2009.

[37] A. Mohammadi-Karakani, S. Asgharzadeh-Haghighi, M. Ghazi-Khansari, and R. Hosseini, "Determination of urinary enzymes as a marker of early renal damage in diabetic patients," Journal of Clinical Laboratory Analysis, vol. 21, no. 6, pp. 413–417, 2007.